INDIANAPOLIS--Eli Lilly and Company's Gemzar (gemcitabine) is
now available for use in the treatment of advanced pancreatic
"As the first new treatment for pancreatic cancer in several
decades, Gemzar represents hope for patients and a breakthrough
for Lilly scientists," said August M. Watanabe, MD, executive
vice president of the company.
Gemzar, a nucleoside analog, is the first chemotherapy agent to
receive FDA clearance based on a unique clinical endpoint--clinical
benefit response--designed to objectively assess the effect of
the drug on measured disease-related symptoms. In two clinical
trials, about one quarter of patients treated with Gemzar demonstrated
improvement in symptoms.
Gemzar is indicated as first-line treatment for patients with
locally advanced (nonresectable stage II or III) or metastatic
(stage IV) adenocarcinoma of the pancreas, and is also indicated
for patients previously treated with fluorouracil.